Article in Japanese

Comparison between the efficacy of cefazolin and cefotaxime for pediatric urinary tract infection

Sadahiro FUKUI^1,2）, Yoshiki KUSAMA^1,2）, Katsunori KAMIMURA^1,2）, Toshiro MAIHARA^2）

Cefotaxime is generally used in the empiric treatment of community-acquired urinary tract infections (UTIs). Cefazolin can also be used as a possible alternative agent in regions where Escherichia coli is susceptible. Herein, we compared the efficacy of cefotaxime and cefazolin in our hospital, where the susceptibility of E. coli to cefazolin is higher than 90% in the antibiogram. We included pediatric patients, aged 2‒36 months, who were hospitalized due to UTIs from January 2018 to July 2021. Patients were classified into those who received cefazolin and those who received cefotaxime. The main outcome was the time between the hospitalization and defervescence. In this study, 25 and 23 patients received cefazolin and cefotaxime, respectively. There were no significant differences in the background factors between the two groups. The time from treatment initiation to defervescence was 17 hours (quartile range: 10-42) in the cefazolin group and 26 hours (8.5-43) in the cefotaxime group; the difference was not significant (p=0.716). The efficacy of cefazolin was not significantly inferior to that of cefotaxime. Cefazolin may be an acceptable agent for empiric treatment of UTIs in regions where E. coli susceptibility to cefazolin is high in children aged 2-36 months.

---

1）Division of General Pediatrics, Department of Pediatrics, Hyogo Prefectural Amagasaki Medical Center

2）Department of Pediatrics, Hyogo Prefectural Amagasaki Medical Center

Key words	pediatric, urinary tract infection, cefazolin, cefotaxime, antimicrobial stewardship
Received	November 17, 2022
Accepted	February 8, 2023

35 (1)：3─10,2023